Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

2.48USD
3:59pm EST
Change (% chg)

$0.05 (+2.06%)
Prev Close
$2.43
Open
$2.40
Day's High
$2.49
Day's Low
$2.39
Volume
320,638
Avg. Vol
386,810
52-wk High
$10.07
52-wk Low
$1.51

IMGN.OQ

Chart for IMGN.OQ

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target... (more)

Overall

Beta: 1.96
Market Cap(Mil.): $212.14
Shares Outstanding(Mil.): 87.30
Dividend: --
Yield (%): --

Financials

  IMGN.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -1.79 -- --
ROI: -73.36 -1.38 14.86
ROE: -- -1.07 16.28

BRIEF-Immunogen announces departure of Sandra Poole

* Poole, executive vice president, technical operations and commercial development, will leave company at end of January Source text for Eikon: Further company coverage:

4:21pm EST

BRIEF-Immunogen says cash balance at Dec 31, 2016 was about $160 mln

* On January 11, 2017, company said that its cash balance at December 31, 2016 (unaudited) was approximately $160 million - SEC filing Source text (http://bit.ly/2jI3xFH) Further company coverage:

Jan 12 2017

BRIEF-Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

* Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

Nov 11 2016

BRIEF-Immunogen CFO Johnston buys 10,000 shares of co's common stock on Nov 2

* Immunogen Inc CFO David Johnston reports open market purchase of 10,000 shares of co's common stock on Nov 2 at $1.70per share Source text: (http://bit.ly/2e5xpJI) Further company coverage:

Nov 03 2016

BRIEF-Immunogen quarterly loss $0.51 per share

* Immunogen reports financial results for quarter ended September 30 and reviews business highlights

Oct 28 2016

BRIEF-Immunogen: Will reduce workforce by 17 pct

* Company will reduce its workforce by 17 pct and seek to partner its non-core b-cell lymphoma programs

Sep 29 2016

BRIEF-Immunogen announces update to financial results year ended June 30, 2016 - SEC filing

* Announces update to financial results for the quarter and year ended June 30, 2016 - SEC filing

Aug 25 2016

BRIEF-Immunogen reports departure of chief development officer

* Immunogen announces departure of chief development officer Source text for Eikon: Further company coverage:

Aug 09 2016

BRIEF-Immunogen Q4 loss per share $0.51

* Immunogen reports fourth quarter and fiscal year 2016 financial results and provides quarterly business update

Aug 04 2016

Competitors

Earnings vs. Estimates